Literature DB >> 17768390

Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.

D K L Cheuk1, P Wang, T L Lee, A K S Chiang, S Y Ha, Y L Lau, G C F Chan.   

Abstract

A cohort of 138 children with 144 hematopoietic stem cell transplantation (HSCT) performed in 1997-2006 were analyzed to evaluate risk factors and mortality predictors of hepatic veno-occlusive disease (VOD). Nineteen patients (13.2%) developed VOD (nine boys, median age 3.5 years) at 1-21 days after HSCT (median 13 days). Age < or =2 years at transplant (odds ratio (OR)=5.25, P=0.011), BU-CY conditioning (OR=5.16, P=0.001), thalassemia major (OR=3.97, P=0.015), platelet engraftment beyond day +21 (OR=8.67, P=0.025) were univariate risk factors for VOD. The first two remained significant in multivariate regression. Seven patients (36.8%) with VOD died, at a median of 44 days post transplant (range, 30-421 days). The 5-year survival was 62%. All surviving patients had normal liver function on follow-up at 0.5-9 years. Patients with VOD had higher 100-day mortality (16.3 vs 9.6%, P=0.024). Mortality predictors included donors other than autologous or matched sibling (hazard ratio (HR)=23.6, P=0.006), hepatic and cutaneous GVHD (HR=8.15, P=0.038), maximal weight gain >9% (HR=6.81, P=0.023), pleural effusion, intensive care unit admission, peak bilirubin >300 micromol l(-1) (HR=13.6, P=0.016), day +21 bilirubin >200 micromol l(-1) (HR=33.9, P=0.001), and rise of bilirubin >15 micromol l(-1) per day within the first week (HR=19.8, P=0.006). Mortality was substantially higher if >3 predictors were present (HR=33.9, P=0.001). Meticulous monitoring in high-risk patients and early treatment should be considered before VOD progresses beyond salvage.

Entities:  

Mesh:

Year:  2007        PMID: 17768390     DOI: 10.1038/sj.bmt.1705835

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  27 in total

1.  Irradiation induces homing of donor endothelial progenitor cells in allogeneic hematopoietic stem cell transplantation.

Authors:  Lingyu Zeng; Shuang Ding; Zhiling Yan; Chong Chen; Wei Sang; Jiang Cao; Hai Cheng; Kailin Xu
Journal:  Int J Hematol       Date:  2012-01-19       Impact factor: 2.490

2.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

3.  Role of Initiating Supportive Care Preceding Veno-occlusive Disease Diagnosis Following Allogeneic Hematopoietic Stem Cell Transplantation in Children.

Authors:  Patricia Rayner; Jessica L Spruit; Roland Chu; Maxim Yankelevich; Meret Henry; Yaddanapudi Ravindranath; Süreyya Savaşan
Journal:  J Pediatr Hematol Oncol       Date:  2019-08       Impact factor: 1.289

4.  Higher plasma bilirubin predicts veno-occlusive disease in early childhood undergoing hematopoietic stem cell transplantation with cyclosporine.

Authors:  Kwi Suk Kim; Aree Moon; Hyoung Jin Kang; Hee Young Shin; Young Hee Choi; Hyang Sook Kim; Sang Geon Kim
Journal:  World J Transplant       Date:  2016-06-24

Review 5.  Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2012-04-24

6.  Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.

Authors:  Aimee C Talleur; Brandon M Triplett; Sara Federico; Ewelina Mamcarz; William Janssen; Jianrong Wu; David Shook; Wing Leung; Wayne L Furman
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-18       Impact factor: 5.742

7.  A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up.

Authors:  K A Kasow; C F Stewart; R C Barfield; N L Wright; C Li; D K Srivastava; W Leung; E M Horwitz; L C Bowman; R Handgretinger; G A Hale
Journal:  Bone Marrow Transplant       Date:  2012-03-19       Impact factor: 5.483

Review 8.  Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation.

Authors:  Mitchell S Cairo; Kenneth R Cooke; Hillard M Lazarus; Nelson Chao
Journal:  Br J Haematol       Date:  2020-03-04       Impact factor: 6.998

9.  Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.

Authors:  M Philippe; S Goutelle; J Guitton; X Fonrose; C Bergeron; P Girard; Y Bertrand; N Bleyzac
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

10.  Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.

Authors:  M Al-Mofareh; M Ayas; A Al-Seraihy; K Siddiqui; A Al-Jefri; I Ghemlas; H Alsaedi; H El-Solh; S Al-Sweedan; B Al-Saud; H Al-Mousa; H Al-Dhekri; R Arnaout; R Mohammed; S Al-Muhsen; A Al-Ahmari
Journal:  Bone Marrow Transplant       Date:  2020-04-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.